Allergan to launch eyelash enhancer

Share this article:

Allergan is gearing up for the launch of Latisse, the first FDA-approved cosmetic eyelash enhancer, with a website and consumer ads in development.

Allergan estimates that global sales of Latisse could exceed $500 million annually. A complete product website, at www.latisse.com, goes live on January 15. Approved in December, the product will land on drugstore shelves in “late January, early February,” according to Heather Katt, an Allergan spokesperson. Consumer ads will launch “when appropriate,” following the availability of the drug, said Katt. Chandler Chicco and Grey, both of New York City, are handling public relations and advertising for Latisse, respectively. California-based Pacific Communications is Allergan's AOR for professional and patient communications in support of Latisse.

Scott Whitcup, Allergan's EVP of research and development, said in a statement that Latisse fulfills an unmet need in the medical aesthetic marketplace by increasing the growth of eyelashes, making them longer, thicker and darker. 

Bimatoprost ophthalmic solution is also marketed as Lumigan, Allergan's glaucoma eye drops. FDA approved Lumigan in 2001, and Allergan discovered its eyelash-enhancing properties through patient reports.

Latisse is available by prescription only, and is recommended as a once-daily treatment. A 30-day supply will cost $120, the Wall Street Journal reported. A 30-day supply of Lumigan, without insurance, costs $185.99 at Walgreens.

Share this article:
close

Next Article in News

Email Newsletters

More in News

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Fabry disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.

Five things for pharma marketers to know: Wednesday, August 20

Five things for pharma marketers to know: Wednesday, ...

Novartis explores the virtual care space, a court has dismissed a lawsuit against IPAB, Doctors Without Borders calls the Ebola outbreak "a complete disaster" and Pfizer becomes the first pharma ...